Contraceptive Drugs and Devices Market By Product Type (Drugs {Oral Contraceptives, Injectable Contraceptives, Emergency Contraceptives, Topical Contraceptives, Vaginal Contraceptives}, Devices {Intrauterine Devices (IUDs), Implants, Male Condoms, Female Condoms, Diaphragms, Contraceptive Sponges}), By Use Method (Short-term Contraceptives, Long-term Contraceptives), By End-User (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, Home Care Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Contraceptive Drugs and Devices market accounted for USD 31.65 Billion in 2024 and is expected to reach USD 61.66 Billion by 2035, growing at a CAGR of around 6.25% between 2025 and 2035.  The contraceptive drugs and devices market is the market for products used to avoid pregnancy, such as hormonal pills, intrauterine devices (IUDs), contraceptive injections, and barriers.

This market has been growing rapidly because of greater awareness related to family planning, new contraceptive technologies, and demand for more effective methods of contraception. Government policy, access to care, and increasing attention to women's health are contributing to market expansion. Furthermore, the growth of non-hormonal and male contraceptive products is anticipated to influence the future of the market.

Report Scope:

Market Dynamics

Growing awareness about reproductive health and family planning.

Greater awareness of reproductive health and family planning has resulted in significant changes worldwide, which drives the Contraceptive Drugs and Devices Market. As educational efforts around contraception increase, individuals are exercising an increased understanding of what is available to them and their reproductive choices. In principle, public health messages, mass media promotion, and educational activities have informed the public about the beneficial role of family planning. This awareness plays a role in decreasing unintended pregnancies and improving perinatal care. The process of educating women results in female parity and hence has been instrumental in the decision-making processes in family planning.
The spread of demand for family planning services expands with increased knowledge of the ability to focus on family planning. In addition, access to family planning providers has expanded to serve underserved populations. Social media and online platforms also speed up the dissemination of it and its related content. Contraception is becoming increasingly acceptable in both culture and society. In the end, raising awareness promotes healthier communities and families around the globe.

Enhanced healthcare access and distribution networks.

Improved healthcare access and logistics systems have greatly enhanced access to contraceptive products, driving the Contraceptive Drugs and Devices Market. Better networks are enabling health and medical services to reach underserved and isolated areas, increasing access to contraception. Government initiatives and partnerships with NGOs have increased outreach programs, providing affordable options to diverse populations. Mobile clinics and telemedicine are addressing gaps in rural regions, providing contraceptive products at the patient's doorstep.

Better supply chains guarantee the continued availability of both the devices and drugs used in contraception and thus prevent stockouts. Public health measures have focused on family planning and distributing it on a large scale. Health insurance coverage for contraceptives has expanded, providing them with greater affordability. Social media and online platforms accelerate the dissemination of it and its associated content. Social and cultural norms are shifting in favor of contraception. Globally, healthier families and communities are ultimately fostered by raising awareness.

High cost of advanced contraceptive devices and medications.

The relatively high cost of sophisticated CMs makes it a huge obstacle for many people, which restrains the Contraceptive Drugs and Devices Market. VIP options, including intrauterine devices (IUDs), implants, and hormonal delivery devices, can be expensive even before delivery. These costs may render long-term family planning infeasible for low-income groups. Insurance reimbursement for such devices is patchy, and many end up without such financial support. The research, development, and production of innovative contraceptives increase costs.

Furthermore, market oligopolies, distribution fees, and excessive imports all raise prices in some regions. People are consequently being forced to pay higher rates due to the lack of supply in rural areas. Due to financial constraints, some patients may choose less effective or non-pharmacological therapy. Women's freedom and choice of reproductive health care are also impacted by financial limitations. Reducing these expenses could help improve family planning equity and accessibility.

 Expanding markets in developing regions for contraceptive access.

The contraceptive drugs and devices market is expected to expand in the upcoming days in developing countries because of awareness of contraception and government support. The efforts of NGOs and governments to provide accessible and reasonably priced contraceptives are improving healthcare equity, particularly for people who are unable to pay for necessities. Reproductive autonomy has been promoted, and well-coordinated public health campaigning has encouraged the public to be receptive to the use of family planning methods.

 To reach even difficult places, the distribution channels are complemented by population density, growth, and the expanded capacity of health services. By disseminating knowledge about the benefits of contraception, improved education initiatives are also in charge of increasing the adoption rate. Developing regions are the primary amenity area for marketplaces for resolved reproductive health requirements because of this unique environment.

 Rising demand for non-hormonal, sustainable contraceptive options.

The growing number of documented negative consequences of hormones has increased the demand for non-hormonal, environmentally friendly forms of birth control. Many people are searching for ways to prevent squandering their natural hormone levels. Non-hormonal techniques, including the copper IUD, fertility awareness-based methods, and barrier methods, provide long-term, proven, and hormone-free contraception. There is a rising interest in green contraceptive options that are in line with the concept of sustainable living. Consumers are increasingly aware of the potential to reduce the environmental footprint of products such as condoms and oral contraceptives.

There is also a demand for nonhormonal alternatives driven by a switch to personalized methods of family planning. These options provide women with greater control over their reproductive health. A non-hormonal approach is attractive to those who seek a hormone-free, relatively low-maintenance approach. They also have reduced side effects and risks compared to hormonal approaches. There will probably remain a positive demand for such facilities as awareness grows.

Industry Experts Opinion

“The availability of OTC contraceptives marks a significant shift in accessibility. It empowers individuals, particularly those in underserved communities, to manage their reproductive health without the barriers of cost or requiring a prescription.”

• Dr. Christina Gibson, member of the British Menopause society and the Faculty of Sexual and Reproductive Healthcare.  

Segment Analysis

Based on Product Type, The Contraceptive Drugs and Devices Market Has been Classified into Drugs and devices. In the contraceptive drugs and devices market, oral contraceptives have been the most dominant and most significant segment. This is mainly because they are used in huge numbers, mainly for the convenience, cost-effectiveness, and efficiency of not allowing pregnancy. The share of oral contraceptives in the market is significantly large, as they have a very long history, and a higher percentage of women are users of these. IUDs also led the devices segment, driven by long-term efficacy and increasing popularity. IUDs are preferred for low maintenance, as one device will provide contraception for years. The combination of oral contraceptives and IUDs is a key part of the market, with both showing significant demand driven by evolving healthcare accessibility and growing women's autonomy in reproductive health.

Based on Product Type, The Contraceptive Drugs and Devices Market Has been Classified into Short-term Contraceptives and long-term Contraceptives. In the contraceptive drugs and devices market, long-term contraceptives are the largest and most important segment. These methods, such as IUDs and contraceptive implants, have attracted a lot of attention because they have a high efficacy and are used for a long time often several years.

The rising desire for long-term options portrays a shift in consumer behavior among individuals, who seek more comfortable, low-maintenance options with few visits to healthcare providers. Long-term contraceptives are also perceived as time-effective, as their need is minimal compared to frequently used alternatives. Increasing reproductive health awareness and increased global access to such options have also driven the dominance of the segment.

Regional Analysis

High levels of healthcare infrastructure, advanced medical technology, and superior reproductive health awareness have made the North American Contraceptive Drugs and Devices Market leader. In areas where there is such a strong need for new contraceptive options and significant governmental focus on family planning, people are taking advantage of public and private opportunities alike. The U.S. and European countries have healthcare systems that provide a broad spectrum of contraceptive options ranging from oral pills to long-acting devices. Insurance coverage, in addition, drives market expansion, resulting in greater availability of contraceptive services to consumers at a lower cost.

The Asia-Pacific Contraceptive Drugs and Devices Market is growing rapidly. Countries such as India and China are also extending family planning projects and new contraceptive techniques. Latin America exhibits growth in part because of better availability of health care services, a growing number of government investments in reproductive health, and shifting social perceptions of family planning.

Africa, with its massive youth population and increasing need for family planning, is quickly implementing modern contraceptive methods. The enhancement of healthcare infrastructure and the support of international organizations are beginning to meet unmet needs in providing access to contraceptives in these areas. Furthermore, the increasing knowledge of non-hormone and eco-friendly contraceptive choices is driving the substantial increase in these developing markets.

Competitive Landscape

This market is highly competitive, with leading contraceptive drugs and device manufacturers in the hands of large pharmaceutical companies and other regional ones. Currently, the market is behind Bayer AG, Pfizer Inc., and Merck & Co. Innovative marketing strategies and an enhanced focus on R&D are hard to overcome. As such, new entrants like Exeltis USA and Ciron Drugs rightly target making formulations affordable to create a market in the developing world. Government-backed companies like HLL Lifecare Limited, which make up the majority of the businesses, significantly contribute to bolstering acquisition restrictions in underserved areas.

Another benefit of market penetration is cooperation with NGOs and other international health organizations. The primary strategy axes are diversification, mergers and acquisitions, and the development of new products, such as self-injectables, biodegradable implants, and bioavailability enhancers. Another growth strategy is connected to the increasing demand for safe, long-acting contraceptives and companies' attempts to improve the effectiveness of their manufactured items and reduce their adverse effects.

Contraceptive Drugs and Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In September 2024, a leading group in women’s health, CooperSurgical, unveiled a novel inserter for single-hand Paragard® insertion. With the introduction of the new single-hand form of the inserter, the insertion procedure is made to better suit the healthcare provider’s needs, and Paragard becomes an even more patient and provider-friendly form of contraceptive.
• In May 2022, NetVation DL Medicine announced a research collaboration with Pfizer Inc. NetVation DL Medicine "DL Medicine", a privately held biotechnology business based in Chengdu, China that is focused on the discovery and development of innovative drug concepts, has established a two-year research collaboration with Pfizer Inc.

Report Coverage:

By Product Type

• Drugs
  • Oral Contraceptives
  • Injectable Contraceptives
  • Emergency Contraceptives
  • Topical Contraceptives
  • Vaginal Contraceptives
• Devices
  • Intrauterine Devices (IUDs)
  • Implants
  • Male Condoms
  • Female Condoms
  • Diaphragms
  • Contraceptive Sponges

By Use Method

• Short-term Contraceptives
• Long-term Contraceptives

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Johnson & Johnson
• Bayer AG
• Pfizer Inc.
• Merck & Co., Inc.
• CooperSurgical, Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V. (Viatris)
• HLL Lifecare Limited
• Reckitt Benckiser Group Plc
• Abbott Laboratories
• Lupin Pharmaceuticals, Inc.
• Ciron Drugs & Pharmaceuticals Pvt. Ltd.
• Exeltis USA, Inc.
• Merck Group
• Amgen Inc.
• Cadila Healthcare Limited
• Piramal Healthcare
• HRA Pharma

Frequently Asked Questions (FAQs)